

# Emmanuel S Antonarakis Mbbch

## List of Publications by Citations

**Source:**

<https://exaly.com/author-pdf/7196464/emmanuel-s-antonarakis-mbbch-publications-by-citations.pdf>

**Version:** 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

305  
papers

15,373  
citations

55  
h-index

117  
g-index

340  
ext. papers

19,471  
ext. citations

6.6  
avg, IF

6.9  
L-index

#	Paper	IF	Citations
305	Detection of circulating tumor DNA in early- and late-stage human malignancies. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 224ra24	17.5	2741
304	AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1028-38	59.2	1753
303	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1402-18 <sup>2.2</sup>	2.2	666
302	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 479-505	7.3	562
301	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , <b>2015</b> , 1, 582-91	13.4	441
300	Ruthenium-based chemotherapeutics: are they ready for prime time?. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 66, 1-9	3.5	358
299	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 650-659	13.4	297
298	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2149-2156	2.2	279
297	and COVID-19: Serendipity or Opportunity for Intervention?. <i>Cancer Discovery</i> , <b>2020</b> , 10, 779-782	24.4	231
296	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 395-405	2.2	216
295	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , <b>2019</b> , 75, 88-99	10.2	216
294	The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. <i>BJU International</i> , <b>2012</b> , 109, 32-9	5.6	177
293	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1120-1129	2.2	171
292	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 269ra2	17.5	149
291	PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Molecular Imaging and Biology</i> , <b>2016</b> , 18, 411-9	3.8	146
290	Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. <i>Oncologist</i> , <b>2013</b> , 18, 163-73	5.7	122
289	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 991-999	2.2	117

288	Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. <i>European Urology</i> , <b>2018</b> , 74, 218-225	10.2	107
287	Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. <i>Clinical Advances in Hematology and Oncology</i> , <b>2013</b> , 11, 14-23	0.6	107
286	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , <b>2018</b> , 19, 76-86	21.7	100
285	Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 46-53	8.9	99
284	The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. <i>European Urology</i> , <b>2014</b> , 66, 646-52	10.2	98
283	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 28561-28571	3.3	92
282	Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1955-61	7.5	91
281	Androgen receptor splice variants in the era of enzalutamide and abiraterone. <i>Hormones and Cancer</i> , <b>2014</b> , 5, 265-73	5	87
280	Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. <i>Drug Design, Development and Therapy</i> , <b>2011</b> , 5, 117-24	4.4	87
279	Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. <i>European Urology</i> , <b>2019</b> , 75, 378-382	10.2	87
278	An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. <i>Cancer</i> , <b>2012</b> , 118, 6063-71	6.4	83
277	Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2881-6	10.3	80
276	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , <b>2018</b> , 188, 1478-1485	5.8	79
275	MSH2 Loss in Primary Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6863-6874	12.9	78
274	Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. <i>European Urology</i> , <b>2016</b> , 70, 963-970	10.2	78
273	Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 to Suppress Enzalutamide-resistant Prostate Cancer Progression. <i>European Urology</i> , <b>2017</b> , 72, 835-844	10.2	74
272	Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. <i>BJU International</i> , <b>2014</b> , 114, E11-E17	5.6	72
271	Very-high-risk localized prostate cancer: definition and outcomes. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2014</b> , 17, 57-63	6.2	72

270	Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. <i>Prostate</i> , <b>2014</b> , 74, 1278-85	4.2	71
269	Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. <i>Cancer Letters</i> , <b>2012</b> , 323, 135-46	9.9	71
268	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 134-143	7.3	71
267	Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 6810-6815	11.5	71
266	A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. <i>Prostate</i> , <b>2015</b> , 75, 1518-25	4.2	70
265	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. <i>European Urology</i> , <b>2019</b> , 76, 452-458	10.2	69
264	Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. <i>Prostate</i> , <b>2018</b> , 78, 401-407	4.2	68
263	Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. <i>Future Oncology</i> , <b>2018</b> , 14, 907-917	3.6	66
262	-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. <i>JCO Precision Oncology</i> , <b>2020</b> , 4, 370-381	3.6	66
261	KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5007-5007	2.2	64
260	Novel targeted therapeutics for metastatic castration-resistant prostate cancer. <i>Cancer Letters</i> , <b>2010</b> , 291, 1-13	9.9	62
259	Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2018</b> , 21, 539-548	6.2	61
258	Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. <i>BJU International</i> , <b>2011</b> , 108, 378-85	5.6	61
257	Expression of AR-V7 and ARv in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1880-1888	12.9	61
256	A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate CancEr (ORIOLE). <i>BMC Cancer</i> , <b>2017</b> , 17, 453	4.8	60
255	Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3544-3551	12.9	59
254	Microsatellite instability in prostate cancer by PCR or next-generation sequencing <b>2018</b> , 6, 29		58
253	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2016</b> , 10, 1-9	1.8	57

252	Castration-resistant prostate cancer: latest evidence and therapeutic implications. <i>Therapeutic Advances in Medical Oncology</i> , <b>2014</b> , 6, 167-79	5.4	55
251	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3181-3188	2.2	53
250	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 475-486	3.8	52
249	Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2011</b> , 14, 192-205	6.2	50
248	Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4986-93	2.2	50
247	Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. <i>Prostate</i> , <b>2017</b> , 77, 33-40	4.2	49
246	Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. <i>European Urology</i> , <b>2019</b> , 76, 170-176	10.2	49
245	Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2451-2459	12.9	48
244	A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 883-92	3.5	48
243	A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 581-8	2.8	47
242	Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. <i>Therapeutic Advances in Urology</i> , <b>2012</b> , 4, 167-78	3.2	46
241	Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2019</b> , 22, 59-65	6.2	46
240	Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. <i>Prostate</i> , <b>2016</b> , 76, 1218-26	4.2	45
239	Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1087-1089	59.2	44
238	Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. <i>Oncologist</i> , <b>2016</b> , 21, 1427-1435	5.7	43
237	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>European Urology</i> , <b>2018</b> , 73, 156-165	10.2	41
236	Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , <b>2017</b> , 9, 565-573	5.4	40
235	Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2018</b> , 73, 727-735	10.2	40

234	Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials. <i>Cancer</i> , <b>2012</b> , 118, 1533-42	6.4	39
233	Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5269-76	12.9	39
232	Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4245-4260	15.9	39
231	Androgen pathway resistance in prostate cancer and therapeutic implications. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 1521-37	4	38
230	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. <i>Journal of Molecular Diagnostics</i> , <b>2017</b> , 19, 115-125	5.1	36
229	Current status of immunological therapies for prostate cancer. <i>Current Opinion in Urology</i> , <b>2010</b> , 20, 241-48	6.8	36
228	p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2018</b> , 21, 260-268	6.2	35
227	Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. <i>International Journal of Urology</i> , <b>2017</b> , 24, 441-448	2.3	34
226	Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4998-5008	2.2	34
225	CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2018</b> , 18, 155-163	3.8	33
224	A phase II trial of ganetespib, a heat shock protein 90 (Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. <i>Investigational New Drugs</i> , <b>2016</b> , 34, 112-8	4.3	33
223	Use of androgen deprivation therapy in prostate cancer: indications and prevalence. <i>Asian Journal of Andrology</i> , <b>2012</b> , 14, 177-86	2.8	33
222	Galeterone for the treatment of advanced prostate cancer: the evidence to date. <i>Drug Design, Development and Therapy</i> , <b>2016</b> , 10, 2289-97	4.4	33
221	A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 1175-84	12.5	32
220	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , <b>2017</b> , 2017,	3.6	32
219	T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3182-3192	12.9	31
218	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. <i>European Journal of Cancer</i> , <b>2019</b> , 114, 107-116	7.5	30
217	Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , <b>2014</b> , 74, 1560-8	4.2	30

216	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	29
215	Tumorigenic potential of circulating prostate tumor cells. <i>Oncotarget</i> , <b>2013</b> , 4, 413-21	3.3	29
214	Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4651-63	12.9	29
213	Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 14800-32	6.3	28
212	Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. <i>European Urology</i> , <b>2020</b> , 78, 652-656	10.2	27
211	The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2012</b> , 110, E575-82	5.6	27
210	Targeting angiogenesis for the treatment of prostate cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2012</b> , 16, 365-76	6.4	27
209	Update: immunological strategies for prostate cancer. <i>Current Urology Reports</i> , <b>2010</b> , 11, 202-7	2.9	27
208	Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. <i>Current Treatment Options in Oncology</i> , <b>2015</b> , 16, 57	5.4	26
207	Sequencing Treatment for Castration-Resistant Prostate Cancer. <i>Current Treatment Options in Oncology</i> , <b>2016</b> , 17, 64	5.4	26
206	Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide. <i>Nature Reviews Urology</i> , <b>2016</b> , 13, 697-698	5.5	26
205	PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 8105-8114	3.6	26
204	When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. <i>European Urology Oncology</i> , <b>2020</b> , 3, 594-611	6.7	26
203	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. <i>European Urology</i> , <b>2019</b> , 75, 929-937	10.2	26
202	Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2020</b> , 77, 14-21	10.2	26
201	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. <i>Prostate</i> , <b>2016</b> , 76, 1484-1490	4.2	25
200	Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 306-315	12.9	24
199	Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2011</b> , 14, 206-18	6.2	23

198	Pan-Cancer Analysis of Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. <i>Oncologist</i> , <b>2019</b> , 24, 1526-1533	5.7	23
197	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 275-282.e1	3.3	22
196	Management of patients with biochemical recurrence after local therapy for prostate cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>2013</b> , 27, 1205-19, viii	3.1	22
195	Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice. <i>Archives of Disease in Childhood</i> , <b>2004</b> , 89, 877-80	2.2	22
194	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1371-1382	2.2	22
193	Treatment strategies for DNA repair-deficient prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 889-898	3.8	21
192	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 105, 948-956	4	21
191	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 562-573	9.7	21
190	Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 76, 843-851	10.2	21
189	Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 69, 763-71	3.5	21
188	Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 581-94	9.6	21
187	Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. <i>Current Opinion in Oncology</i> , <b>2012</b> , 24, 258-65	4.2	21
186	The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 18-18	2.2	21
185	Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer. <i>Cancers</i> , <b>2015</b> , 7, 1983-93	6.6	21
184	Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	21
183	Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. <i>Academic Radiology</i> , <b>2018</b> , 25, 1405-1414	4.3	20
182	Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer. <i>Current Urology Reports</i> , <b>2016</b> , 17, 29	2.9	20
181	Resistance to androgen-pathway drugs in prostate cancer. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 2234	59.2	20

180	The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. <i>Prostate</i> , <b>2011</b> , 71, 1608-15	4.2	20
179	Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5005-5005	2.2	20
178	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , <b>2021</b> , 4, 447-455	6.7	20
177	BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 1391-1397	5.9	19
176	Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3507-3517	2.2	19
175	Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. <i>Core Evidence</i> , <b>2013</b> , 8, 27-35	4.9	19
174	Detection fidelity of AR mutations in plasma derived cell-free DNA. <i>Oncotarget</i> , <b>2017</b> , 8, 15651-15662	3.3	19
173	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. <i>Oncogene</i> , <b>2020</b> , 39, 6935-6949	9.2	19
172	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	18
171	Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. <i>Prostate</i> , <b>2020</b> , 80, 527-544	4.2	18
170	PARP inhibitors for homologous recombination-deficient prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , <b>2018</b> , 23, 123-133	3.7	18
169	Darolutamide For Castration-Resistant Prostate Cancer. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 8769-8777	4.4	18
168	Surgical resection of malignant melanoma metastatic to the pancreas: case series and review of literature. <i>Journal of Gastrointestinal Cancer</i> , <b>2012</b> , 43, 431-6	1.6	18
167	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. <i>Nature Cancer</i> , <b>2020</b> , 1, 1082-1096	15.4	18
166	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 35, 131-41	7.1	18
165	Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , <b>2017</b> , 15, 785-795	0.6	18
164	Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 367-380	6.2	17
163	Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations. <i>International Journal of Urology</i> , <b>2016</b> , 23, 646-53	2.3	17

162	Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence?. <i>Pediatric Blood and Cancer</i> , <b>2004</b> , 43, 651-8	3	17
161	A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 184-193	6.2	17
160	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , <b>2021</b> , 79, 692-699	10.2	17
159	Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 381-397	6.2	16
158	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 136, 16-24	7.5	16
157	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. <i>Oncotarget</i> , <b>2017</b> , 8, 104182-104192	3.3	16
156	The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2014</b> , 17, 28-33	6.2	16
155	Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5035-5035	2.2	16
154	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 811-819	2.3	16
153	Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis. <i>Cancer Cell</i> , <b>2021</b> , 39, 68-82.e9	24.3	16
152	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	15
151	The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2018</b> , 21, 306-318	6.2	15
150	Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 1297-1304	3.5	15
149	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. <i>Prostate</i> , <b>2016</b> , 76, 512-20	4.2	15
148	Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4662-4671	12.9	15
147	Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. <i>Human Vaccines and Immunotherapeutics</i> , <b>2012</b> , 8, 509-19	4.4	15
146	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. <i>World Journal of Urology</i> , <b>2019</b> , 37, 2623-2629	4	15
145	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. <i>Modern Pathology</i> , <b>2021</b> , 34, 1185-1193	9.8	15

144	A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer. <i>Oncologist</i> , <b>2019</b> , 24, 430-432	5.7	14
143	A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. <i>Prostate</i> , <b>2019</b> , 79, 1597-1603	4.2	14
142	An atypical complication of atypical pneumonia. <i>American Journal of Medicine</i> , <b>2006</b> , 119, 824-7	2.4	14
141	Chemotherapy and its evolving role in the management of advanced prostate cancer. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 334-40	2.8	14
140	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , <b>2020</b> , 59, 225-239	5	14
139	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , <b>2021</b> , 80, 632-640	10.2	14
138	Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches. <i>Cancer Treatment and Research Communications</i> , <b>2020</b> , 23, 100164	2	13
137	Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype. <i>Prostate</i> , <b>2019</b> , 79, 1572-1579	4.2	13
136	Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. <i>Prostate</i> , <b>2015</b> , 75, 1814-20	4.2	13
135	Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. <i>Prostate</i> , <b>2012</b> , 72, 487-98	4.2	13
134	Images in clinical medicine. Acquired leukonychia totalis. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, e2	59.2	13
133	Temperature modulation of DHPLC analysis for detection of coexisting constitutional and mosaic sequence variants in TSC2. <i>Journal of Proteomics</i> , <b>2002</b> , 51, 161-4		13
132	A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS5072-TPS5072	2.2	13
131	The STAMPEDE trial: paradigm-changing data through innovative trial design. <i>Translational Cancer Research</i> , <b>2016</b> , 5, S485-S490	0.3	13
130	Liquid biopsy: Clues on prostate cancer drug resistance. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 312fs45	17.5	12
129	The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 2689	17.4	12
128	The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 32-8	3.3	12
127	Clinical problem-solving. Beware of first impressions. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 628-34	39.2	12

126	A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA <b>2014</b> , 2, 21-32		12
125	CDK12 inactivation across solid tumors: an actionable genetic subtype. <i>Oncoscience</i> , <b>2019</b> , 6, 312-316	0.8	12
124	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , <b>2021</b> , 26, e270-e278	5.7	12
123	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1623-1630	12.9	12
122	Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. <i>Prostate</i> , <b>2020</b> , 80, 407-414	4.2	11
121	Clinical implications of mismatch repair deficiency in prostate cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 2395-2411	4.1	11
120	The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. <i>Prostate</i> , <b>2017</b> , 77, 1303-1311	4.2	11
119	Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?. <i>Nature Clinical Practice Oncology</i> , <b>2009</b> , 6, 12-3		11
118	PARP inhibition - not all gene mutations are created equal. <i>Nature Reviews Urology</i> , <b>2019</b> , 16, 4-6	5.5	11
117	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 109, 387-395	4	11
116	High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, e51-3	3.3	10
115	Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis. <i>Prostate Cancer</i> , <b>2017</b> , 2017, 8560827	1.9	10
114	Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects. <i>Expert Opinion on Investigational Drugs</i> , <b>2010</b> , 19, 311-4	5.9	10
113	Current status of immunological approaches for the treatment of prostate cancer. <i>Current Opinion in Urology</i> , <b>2012</b> , 22, 197-202	2.8	10
112	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 36, 131-141	7.1	10
111	Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. <i>Prostate</i> , <b>2020</b> , 80, 1012-1023	4.2	10
110	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2016</b> , 23, 279-90	4	10
109	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>JCO Precision Oncology</i> , <b>2018</b> , 2018,	3.6	10

108	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 470-475. <sup>3.3</sup> 8	9
107	Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012) <sup>2.2</sup> 8	9
106	Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5075-5075 <sup>2.2</sup> 8	9
105	Paraneoplastic palmar fasciitis and polyarthrits syndrome in a patient with advanced prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, e15-23 <sup>3.3</sup> 8	8
104	Prostate cancer: AR splice variant dimerization-clinical implications. <i>Nature Reviews Urology</i> , <b>2015</b> , 12, 431-3 <sup>5.5</sup> 8	8
103	Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer. <i>Asian Journal of Andrology</i> , <b>2012</b> , 14, 520-1 <sup>2.8</sup> 8	8
102	Future directions in castrate-resistant prostate cancer therapy. <i>Clinical Genitourinary Cancer</i> , <b>2010</b> , 8, 37-46 <sup>3.3</sup> 8	8
101	AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5012-5012 <sup>2.2</sup> 8	8
100	Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 216-216 <sup>2.2</sup> 8	8
99	Germline BLM mutations and metastatic prostate cancer. <i>Prostate</i> , <b>2020</b> , 80, 235-237 <sup>4.2</sup> 8	8
98	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , <b>2021</b> , 81, 433-439 <sup>4.2</sup> 8	8
97	β-Particle-Emitter Radiopharmaceutical Therapy: Resistance Is Futile. <i>Cancer Research</i> , <b>2019</b> , 79, 5479-5481. <sup>4.1</sup> 8	8
96	Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial. <i>Prostate</i> , <b>2021</b> , 81, 326-338 <sup>4.2</sup> 8	8
95	Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?. <i>Lancet Oncology</i> , <b>2018</b> , 19, 860-861 <sup>21.7</sup> 7	7
94	Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5077-5077 <sup>2.2</sup> 7	7
93	Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5045-5045 <sup>2.2</sup> 7	7
92	KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5543-5543 <sup>2.2</sup> 7	7
91	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3017-3027 <sup>12.9</sup> 7	7

90	Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	7
89	A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 1052-1060	4.3	6
88	Therapeutic targeting of the DNA damage response in prostate cancer. <i>Current Opinion in Oncology</i> , <b>2020</b> , 32, 216-222	4.2	6
87	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). <i>BMC Cancer</i> , <b>2020</b> , 20, 492	4.8	6
86	Prostate angiosarcoma: a case report and literature review. <i>Medical Oncology</i> , <b>2012</b> , 29, 2901-3	3.7	6
85	Immunotherapy for prostate cancer enters its golden age. <i>Clinical Medicine Insights: Oncology</i> , <b>2012</b> , 6, 263-73	1.8	6
84	Enzalutamide: The emperor of all anti-androgens. <i>Translational Andrology and Urology</i> , <b>2013</b> , 2, 119-120	2.3	6
83	Genomic and Clinicopathologic Characterization of -deficient Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4869-4881	12.9	6
82	Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation. <i>Urology Case Reports</i> , <b>2018</b> , 17, 22-25	0.5	5
81	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 74-83	7.5	5
80	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4077-4088	12.9	5
79	AR-V7 and treatment selection in advanced prostate cancer: are we there yet?. <i>Precision Cancer Medicine</i> , <b>2018</b> , 1,	1	5
78	Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. <i>Oral Oncology</i> , <b>2018</b> , 84, 134-136	4.4	4
77	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2184-2186	2.2	4
76	Prostate angiosarcoma: is there any association with previous radiation therapy?. <i>BJU International</i> , <b>2012</b> , 110, E819-25	5.6	4
75	Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. <i>Clinical Medicine Insights Urology</i> , <b>2013</b> , 2013, 1-14	0	4
74	Pemberton sign. <i>Mayo Clinic Proceedings</i> , <b>2007</b> , 82, 859	6.4	4
73	Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel-based chemotherapy: Results of a Prostate Cancer Clinical Trials Consortium (PCCTC) study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5085-5095	2.2	4

72	Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 807-8	2.8	4
71	Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy. <i>Cancer Research</i> , <b>2020</b> , 80, 868-876	10.1	4
70	AR Splicing Variants and Resistance to AR Targeting Agents. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
69	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 1430-1437	8.9	4
68	Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> ,	6.2	4
67	The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer. <i>Urologic Clinics of North America</i> , <b>2012</b> , 39, 573-81	2.9	3
66	Rheumatoid arthritis masked by docetaxel chemotherapy in a patient with ovarian carcinoma. <i>Journal of Clinical Rheumatology</i> , <b>2008</b> , 14, 121	1.1	3
65	A cut above. <i>American Journal of Medicine</i> , <b>2007</b> , 120, 1031-3	2.4	3
64	Orientation of the stethoscope around the neck: a random phenomenon or an indicator of cerebral lateralisation? Cross-sectional survey. <i>Laterality</i> , <b>2006</b> , 11, 287-93	2	3
63	Phase II trial of rucaparib (Without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS5095-TPS5095	2.2	3
62	Clinical and genomic features of SPOP-mutant prostate cancer. <i>Prostate</i> , <b>2021</b> , 82, 260	4.2	3
61	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 5948-5962	10.1	3
60	Abiraterone acetate for prostate cancer: a new era of hormonal therapies. <i>Asian Journal of Andrology</i> , <b>2011</b> , 13, 663-4	2.8	3
59	Olaparib for DNA repair-deficient prostate cancer - one for all, or all for one?. <i>Nature Reviews Clinical Oncology</i> , <b>2020</b> , 17, 455-456	19.4	3
58	Mismatch repair-deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade. <i>Journal of Physical Education and Sports Management</i> , <b>2021</b> , 7,	2.8	3
57	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 302-309	7.5	3
56	Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> ,	3.3	3
55	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). <i>BMC Cancer</i> , <b>2019</b> , 19, 572	4.8	2

54	Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion. <i>Journal of Oncology Practice</i> , <b>2017</b> , 13, 21-24	3.1	2
53	Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data. <i>Journal of Medical Economics</i> , <b>2019</b> , 22, 1080-1087	2.4	2
52	Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?. <i>Nature Reviews Urology</i> , <b>2008</b> , 5, 480-1		2
51	Acute psychological stress-induced water intoxication. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2005</b> , 9, 142-4	2.4	2
50	Abstract CT134: Androgen receptor (AR) mutations in patients (pts) with castration-resistant prostate cancer (CRPC) with and without prior abiraterone acetate (AA) treatment <b>2015</b> ,		2
49	Association of metastasis-free survival (MFS) with overall survival (OS) in men with PSA-recurrent prostate cancer treated with deferred androgen-deprivation therapy.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 109-109	2.2	2
48	E2809: Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in men with rising PSA at high-risk of progression after local prostate cancer (PC) treatment.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9-9	2.2	2
47	Treatment of Castration-Resistant Prostate Cancer <b>2012</b> , 2954-2971.e4		2
46	TGM4: an immunogenic prostate-restricted antigen <b>2021</b> , 9,		2
45	Differential Activity of PARP Inhibitors in - Versus -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	2
44	Targeting the spectrum of immune checkpoints in prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 1253-1266	3.8	2
43	Medical hospitalizations in prostate cancer survivors. <i>Medical Oncology</i> , <b>2016</b> , 33, 81	3.7	2
42	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , <b>2021</b> , 30, 47-62	0.9	2
41	Targeting lineage plasticity in prostate cancer. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1338-1340	21.7	1
40	Inherited HSD3B1 polymorphisms and hormonal therapy resistance. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1347-1349		1
39	Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz@ Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Lubner, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. <i>J Clin Oncol</i> 2017;35:3110-56. AR-V7 Testing: What's in it for the Patient? Estimating the Clinical Utility. <i>European Urology</i> 2017; 72, e170-e171	10.2	1
38	Abiraterone acetate: a hat trick of clinical benefits. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 1173-4	21.7	1
37	The unfolding treatment landscape for men with castration-resistant prostate cancer. <i>Clinical Investigation</i> , <b>2011</b> , 1, 1533-1544		1

36	Flagellate erythema secondary to bleomycin. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2012</b> , 105, 901	2.7	1
35	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2022</b> ,	6.2	1
34	Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16539-e16539	3.2	1
33	Management of metastatic castration-resistant prostate cancer <b>2011</b> , 6, 90-96		1
32	Supraphysiological testosterone induces ferroptosis and activates NF-kappaB mediated immune pathways in prostate cancer through nucleophagy		1
31	Sipuleucel-T (sip-T) induced proliferative CD8+ T-cell responses to immunizing and secondary antigens.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 165-165	2.2	1
30	Reimagining Vaccines for Prostate Cancer: Back to the Future. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5056-5058	5.8	1
29	Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1625-1632	4	1
28	Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer. <i>Prostate</i> , <b>2021</b> , 81, 572-579	4.2	1
27	Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e365-e368	3.3	1
26	Detection of Early Progression with F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 1270-1273	8.9	1
25	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. <i>Prostate</i> , <b>2021</b> , 81, 1382-1389	4.2	1
24	New approaches to targeting the androgen receptor pathway in prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , <b>2021</b> , 19, 228-240	0.6	1
23	Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability.. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> ,	3.3	1
22	Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302. <i>Prostate</i> , <b>2019</b> , 79, 929-933	4.2	0
21	Does sequencing order of antiandrogens in prostate cancer matter?. <i>Nature Reviews Urology</i> , <b>2020</b> , 17, 197-198	5.5	0
20	Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells. <i>Aging</i> , <b>2020</b> , 12, 17694-17712	5.6	0
19	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.. <i>European Urology Open Science</i> , <b>2021</b> , 34, 70-78	0.9	0

18	Clinical Significance of AR-V567es in Prostate Cancer-Response. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6010-6011	6.0	o
17	Deficiency and the Immune Microenvironment in Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 380-382	12.9	o
16	Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	o
15	The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 1-9	3.5	o
14	Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. <i>European Urology Open Science</i> , <b>2022</b> , 41, 112-115	0.9	o
13	Editorial Comment. <i>Journal of Urology</i> , <b>2017</b> , 197, 142	2.5	
12	Reply to P. Mathew. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e198-e198	2.2	
11	Visual vignette. Necrobiosis lipoidica. <i>Endocrine Practice</i> , <b>2007</b> , 13, 322	3.2	
10	Not what it seems. <i>American Journal of Medicine</i> , <b>2007</b> , 120, 408-11	2.4	
9	Comparison of healthcare resource use and treatment among prostate cancer patients with and without DNA damage repair gene mutations.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e17059-e17059	2.2	
8	Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 308-308	2.2	
7	Bipolar androgen therapy (BAT) in men with hormone sensitive (HS) prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 236-236	2.2	
6	Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 103-103	2.2	
5	Cost-benefit analysis of AR-V7 testing in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) eligible for abiraterone (Abi) or enzalutamide (Enza).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 283-283	2.2	
4	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS5094-TPS5094	2.2	
3	Reply to Salma Kaochar, Nicholas Mitsiades Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzeig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. <i>Eur Urol</i> 2020, 78:652-6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer? SPOP Lumbosacral Plexus Involvement as the First Site of Metastatic Recurrence in a Patient With	10.2	
2	CTNNB1-Mutant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e417-22	3.3	
1	Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 157-157	2.2	

